ExuberaTM on Hold

Final FDA approval of the only inhalable insulin to receive backing by an FDA panel has been put off for at least three months. The marketing go-ahead was expected last week.

Pfizer, Sanofi-Aventis, and Nektar Therapeutics, developers of the system, were notified last Friday that the FDA wanted to conduct an extended review of their "technical chemistry data".

________
For Pfizer and Sanofi-Aventis press release:
Pfizer and Sanofi-Aventis Statement on Status of Exubera

For a news summary:
FDA Delays Decision on Inhalable Insulin